Filtered By:
Cancer: Adenocarcinoma
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 915 results found since Jan 2013.
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
DISCUSSION: This trial will help define the best neoadjuvant treatment sequence for borderline resectable PDAC and aims to evaluate if a total neoadjuvant treatment integrating iHD-SBRT improves the patients' oncological outcomes.TRIAL REGISTRATION: The study was registered at ClinicalTrails.gov (NCT05083247) on October 19th, 2021, and in the Clinical Trials Information System (CTIS) EU CT database (2022-501181-22-01) on July 2022.PMID:37735634 | DOI:10.1186/s12885-023-11327-x
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Christelle Bouchart Julie Navez Ivan Borbath Karen Geboes Timon Vandamme Jean Closset Luigi Moretti Pieter Demetter Marianne Paesmans Jean-Luc Van Laethem Source Type: research
PD-1 blockade induces reactivation of non-productive T cell responses characterized by NF-kB signaling in patients with pancreatic cancer
CONCLUSIONS: Cytotoxic T cells in the blood of PDAC patients remain sensitive to reinvigoration by PD-1 blockade and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti-PD-1 reinvigoration and marks these T cells as non-productive contributors to anti-tumor immunity.PMID:37733830 | DOI:10.1158/1078-0432.CCR-23-1444
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Lestat R Ali Patrick J Lenehan Victoire Cardot-Ruffino Andressa Dias Costa Matthew H G Katz Todd W Bauer Jonathan A Nowak Brian M Wolpin Thomas A Abrams Anuj Patel Thomas E Clancy Jiping Wang Joseph D Mancias Matthew J Reilley Chee-Chee H Stucky Tanios S Source Type: research
Presentation of Gastrointestinal Stromal Tumor, Pancreatic Adenocarcinoma, and Gastric Adenocarcinoma in a Woman With No Identifiable Genetic Abnormalities
This report details the first known case of co-occurrence of gastrointestinal stromal tumor (GIST), pancreatic adenocarcinoma, and gastric adenocarcinoma in an individual with no identifiable genetic abnormalities. The patient is a 57-year-old female who presented with abdominal pain. CT scan demonstrated a pancreatic mass, and endoscopic ultrasound demonstrated an additional gastric mass. Biopsy of both masses demonstrated adenocarcinoma; however, the masses were found to have different origins. The patient underwent neoadjuvant chemotherapy with excellent response. She then underwent surgical intervention, which demonstr...
Source: The American Surgeon - September 12, 2023 Category: Surgery Authors: Catherine Read Marybeth Hughes Omar Itani Source Type: research
Neoadjuvant Gastric Score: How Response to Neoadjuvant Chemotherapy Affects Overall Survival and Adjuvant Benefit
CONCLUSION: NAR score may be repurposed to generate a prognostic tool in gastric adenocarcinoma to predict 5-year OS and has the potential to guide decision-making regarding allocation of adjuvant therapy. Further studies should prospectively validate these findings to confirm clinical utility.PMID:37659978 | DOI:10.1245/s10434-023-14259-9
Source: Ann Oncol - September 2, 2023 Category: Cancer & Oncology Authors: Chase J Wehrle Caleb N Seavey Jenny Chang Katherine Stackhouse Kimberly Woo Toms Augustin Daniel Joyce Robert Simon R Matthew Walsh Samer A Naffouje Source Type: research
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre randomised controlled NeoRes II trial
CONCLUSION: Prolonged time to surgery did not improve histological complete response or other pathological endpoints, while there was a strong trend towards worse survival, suggesting caution in routinely delaying surgery for more than six weeks after nCRT.PMID:37657554 | DOI:10.1016/j.annonc.2023.08.010
Source: Ann Oncol - September 1, 2023 Category: Cancer & Oncology Authors: K Nilsson F Klevebro B Sunde I Rouvelas M Lindblad E Szabo I Halldestam U Smedh B Wallner J Johansson G Johnsen E K Aahlin H-O Johannessen G Alexandersson von D öbeln G O Hjortland N Wang Y Shang D Borg A Quaas I Bartella C Bruns W Schr öder M Nilsson Source Type: research
Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study
CONCLUSIONS: Delayed treatment approaching 2 months was observed in 10% of the population. The rising temporal trend in TTT may be attributed to the increasing shift toward neoadjuvant CT/RT in early-stage PDAC and/or the increasing use of tissue biopsy prior to surgery.PMID:37624518 | DOI:10.1245/s10434-023-14221-9
Source: Ann Oncol - August 25, 2023 Category: Cancer & Oncology Authors: Kavin Sugumar Jonathan J Hue Shreya Gupta Mohamedraed Elshami Luke D Rothermel Lee M Ocuin John B Ammori Jeffrey M Hardacre Jordan M Winter Source Type: research
Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy
Radiat Oncol. 2023 Aug 18;18(1):137. doi: 10.1186/s13014-023-02328-y.ABSTRACTDespite combination chemotherapy demonstrating a positive effect on survival, the clinical outcomes of pancreatic adenocarcinoma (PDAC) remain poor. Radiotherapy was previously a component of the curative treatment of PDAC. Advances in imaging and computer sciences have enabled the prescription of higher dosage of radiation focused on tumours with minimal toxicity to normal tissue. However, the role of radiotherapy has not been established in the curative treatment of localized PDAC because of the conflicting results from large prospective trials....
Source: Cancer Control - August 18, 2023 Category: Cancer & Oncology Authors: I-Shiow Jan Hui Ju Ch'ang Source Type: research
Pattern and time point of relapse in locally advanced esophagogastric adenocarcinoma after multimodal treatment: implications for a useful structured follow-up
CONCLUSIONS: The risk of relapse differs significantly between high- and low-risk patients. Only a part of relapses is associated with clinical symptoms. An individualized follow-up strategy is recommended for high- and low-risk patients considering the individual risk of relapse.PMID:37589924 | DOI:10.1007/s00432-023-05254-4
Source: Clin Med Res - August 17, 2023 Category: Research Authors: Ramona Stelmach Leonidas Apostolidis Steffen Kahle Leila Sisic Henrik Nienh üser Tim Frederik Weber Dirk J äger Georg Martin Haag Source Type: research
Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges
CONCLUSION: Using a tumor marker gene test to personalize an individual's CA19-9 reference range significantly improves diagnostic accuracy.PMID:37566230 | DOI:10.1158/1078-0432.CCR-23-0655
Source: Clinical Cancer Research - August 11, 2023 Category: Cancer & Oncology Authors: Mohamad Dbouk Toshiya Abe Chiho Koi Yohei Ando Helena Saba Elizabeth Abou Diwan Anne Macgregor-Das Amanda L Blackford Evelina Mocci Katie Beierl Ali Dbouk Jin He Richard Burkhart Anne Marie Lennon Lori Sokoll Marcia Irene Canto James R Eshleman Michael Go Source Type: research
